


Informatics and Computer Simulations: Experience of SPARC

23rd May 2019, Budapest

BSE:532872 • NSE: SPARC • BLOOMBERG: SPADV@IN • REUTERS: SPRC.BO • CIN:L73100GJ2006PLC047837 © 2017 - Sun Pharma Advanced Research Company Limited (SPARC). All Rights Reserved



Computational Simulations of Pharmaceutical Formulations: A Case study



Topics



- 1. Components
- 2. Parameters for analysis
- 3. Evolution from packing to nanoparticle formation
- 4. Snapshots of nanoparticle formation
- 5. Analysis
- 6. Summary

System input




Total number of atoms 327376 Ensemble: NPT Total simulation time: 200ns


Formulation components (considering one half of original system):

Drug molecule	30
Fatty acid	15
PEG	456
Cholesterol	4
PVP	6
Ethanol	543
Water	99270
Sodium ions for neutral pH	4
TOTAL	100,327

Molecular Structures







Computational Pharmaceutics



Parameters considered for analysis are:


H-bond analysis

RMSD

Potential energy


Simulating Drug Molecule...






MD simulation






T=20 ns






T=40 ns






T=40 ns






T=60 ns






T=80 ns






T=100 ns






T=120 ns






T=140 ns






T=160 ns






T=180 ns






T=200 ns






Nanoparticle simulation snapshots...





Nanoparticle simulation snapshots...





Analysis...




H-bond analysis


RMSD

Potential energy

H-bond analysis







Other systems studied...



System	Drug	NoPVP	NoPEG	NoFA	NoCHO
Average_Drug-Drug	15.14	31.28	32.80	23.57	29.58
Average_Drug-PVP	3.45	-	7.93	9.24	8.18
Average_Drug-PEG	4.04	15.23	-	16.10	14.91
Average_Drug-FA	0.48	4.28	5.84	_	2.85
Average_Drug-CHO	0.053	0.75	1.36	0.086	-

Removal of PVP, PEG, FA and CHO increases Drug-Drug H-bonds

Role of PEG seems increasing as soon as any of the excipients are removed – which means that in the absence of any of the components Drug can still form aggregates in the presence of PEG





- Composition is as per the experimental stoichiometry
- □ Simulation carried for 200 ns parameters studies are stable
- □ Studies conducted also without PVP, PEG, CHO, FA. PVP and PEG has a larger role in NP stabilization in comparison with CHO and FA
- □ Length of the nanoparticle ~10nm (exclusion PEG, water, EtOH)
- UWidth is ~7nm
- This study can help us understand the role of each excipient in such formulations and help in optimizing formulations
- Computational optimization can be leveraged for difficult to formulate drugs

Acknowledgments



Dr. C. T. Rao Head Drug Discovery

Dr. Ajay Khopade VP, FDD

My colleagues

Dr. Malay Shah, Akbar Shaikh, Dr. Vaibhav Jain and Chetan Puri

And

Sun Pharma Advanced Research Company Limited Vadodara, Gujarat, India





Thank You

© 2017 Sun Pharma Advanced Research Company Limited., All Rights Reserved.

The SPARC Logo is a trademarks of Sun Pharma Advanced Research Company Ltd. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material is for use during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of the Company.